Last update Aug. 23, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dinoprost trometamol is also known as
Dinoprost trometamol in other languages or writings:
Dinoprost trometamol belongs to this group or family:
Main tradenames from several countries containing Dinoprost trometamol in its composition:
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Dinoprost or Prostaglandin F2α is used for termination of pregnancy and missed miscarriage, hydatidiform mole, and intra-uterine fetal death. It has a higher incidence of adverse effects than dinoprostone and is therefore not recommended for labor induction. It is administered intraamniotically.
Since the last update we have not found published data on its excretion in breastmilk.
Its very rapid elimination from plasma make it highly unlikely that significant quantities will pass into breast milk.
It is a natural component of breast milk (Shimizu 1992, Neu 1988, Alzina 1986, Friedman 1986, Lucas 1980) that changes concentration during breastfeeding. (Ylikorkala 1981). Prostaglandins in breast milk can protect the integrity of gastro-intestinal epithelial cells in infants. (Bedrick 1989)